Knight TherapeuticsTSX:GUD +1.30%73 Net Margin % is 8.87% as of Mar. 2026, which is 36% below its 10-year median of 13.76. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.63 (Fairly Valued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Knight Therapeutics ranks worse than 63.49% on this metric.
The historical rank and industry rank for Knight Therapeutics's Net Margin % or its related term are showing as below:
TSX:GUD'
s Net Margin % Range Over the Past 10 Years
Min: -10.18 Med: 13.76 Max: 312.46
Current: 1.1
TSX:GUD's Net Margin % is ranked worse than 63.49% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs TSX:GUD: 1.10
Knight Therapeutics (TSX:GUD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Knight Therapeutics Net Margin % Related Terms
Knight Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (TSX:GUD) has a Net Margin % of 8.87% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Knight Therapeutics and its competitors. This is 36% below median its historical median of 13.76. According to the industry distribution chart, Knight Therapeutics ranks #607 out of 956 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Knight Therapeutics' Net Margin % too high?
Knight Therapeutics' current Net Margin % of 8.87% is 36% below median its 10-year median of 13.76. The Drug Manufacturers industry median Net Margin % is 5.56. Knight Therapeutics' value of 8.87% is 59.5% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #607 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #607 out of 956 companies for Net Margin %. This places Knight Therapeutics in the lower half of its industry. The industry median Net Margin % is 5.56. Knight Therapeutics' value of 8.87% is 59.5% above this benchmark. While the company's 10-year median is 13.76 vs. the industry median of 5.56, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current Net Margin % of 8.87% is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current Net Margin % is 8.87%, which is 36% below median its own 10-year median of 13.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$8.63, compared to a current price of C$9.35 — trading 8.3% above its estimated fair value. The current Net Margin % is 8.87%, which is 36% below median its 10-year median of 13.76 and 59.5% above the Drug Manufacturers industry median of 5.56. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Net Margin % is 8.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.35 is trading 8.3% above its estimated GF Value™ of C$8.63.
GuruFocus considers Knight Therapeutics to be Fairly Valued.
Key valuation signals for TSX:GUD:
Net Margin %: 8.87% (36% below median its 10-year median of 13.76)
GF Value™: C$8.63 vs. price of C$9.35 (8.3% above fair value)
Industry Position: 59.5% above the Drug Manufacturers median (#607 of 956)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for TSX:GUD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
